Compugen Ltd.

NASDAQ:CGEN

2 (USD) • At close January 14, 2025
Bedrijfsnaam Compugen Ltd.
Symbool CGEN
Munteenheid USD
Prijs 2
Beurswaarde 179,072,800
Dividendpercentage 0%
52-weken bereik 1.35 - 3.03
Industrie Biotechnology
Sector Healthcare
CEO Dr. Anat Cohen-Dayag Ph.D.
Website https://cgen.com

An error occurred while fetching data.

Over Compugen Ltd.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a

Vergelijkbare Aandelen

NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE

11.84 USD

Quipt Home Medical Corp. logo

Quipt Home Medical Corp.

QIPT

3.05 USD

Savara Inc. logo

Savara Inc.

SVRA

2.72 USD

Clene Inc. logo

Clene Inc.

CLNN

4.8 USD

Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc.

FENC

5.64 USD

Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

1.34 USD

High Tide Inc. logo

High Tide Inc.

HITI

3.09 USD

Meihua International Medical Technologies Co., Ltd. logo

Meihua International Medical Technologies Co., Ltd.

MHUA

0.317 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)